WENA: Anew Medical, Inc. Average Forecast Price
Anew Medical, Inc. (WENA) relies on the automation of molecular analysis, which accelerates laboratory testing with a small staff of scientists. The strategy is based on creating long-term patents for neurodegeneration therapy, ensuring stable demand for the drugs. The current indicator is 0.00. The price chart below demonstrates the asset's dynamics, while the venture status of the management ties investor interest to the timelines of clinical trials.
Analytical breakdowns for Anew Medical (WENA)
- market price and analyst price targets:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Anew Medical, Inc.|WENA - Long-Term Debt to Capital|Current Liabilities to Capital Anew Medical Inc.|WENA - Company Total Debt|Debts to Book Capitalization Anew Medical|WENA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Anew Medical|Immediate Liquidity anewmeds.com
- net income and valuation multiples indicators:
WENA - Net Profit|Projected Future Earnings Anew Medical, Inc.|WENA - Price to Earnings Ratio|Price to Future Earnings Ratio anewmeds.com|WENA - PEG Multiple|Company Value to EBITDA Anew Medical|WENA - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Anew Medical|WENA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months anewmeds.com|WENA - Earnings per share growth in current year|Expected earnings per share growth for next year Anew Medical, Inc.
Summary company analytics:WENA anewmeds.com
A comparative asset analysis requires benchmarking market quotes against the mathematical average of institutional analysts' daily targets to determine fair value. This model measures the speed of capital adaptation to FDA regulatory risks and the biotechnology patent protection of Anew Medical, Inc. (WENA), allowing investors to avoid overpaying for the asset under strict oversight by utilizing the average investment bank forecast for the stock.
Competitors of Anew Medical, Inc.
Consensus Target biogen.com BIIB|Analyst Consensus Forecast NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd (RGC) - Average Forecast Price|AXSM - Price Target Chart|ACAD (ACADIA Corp) - Broker Consensus Forecast|XENE: Analyst Consensus Forecast|vikingtherapeutics.com (VKTX) - Analyst Consensus Forecast|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Analyst Consensus Forecast Alector Therapeutics|Price Target Chart Annexon (ANNX)|omeros.com - Broker Consensus Forecast|Analyst Consensus Forecast NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Average Forecast Price|VYGR: Consensus Target|neumoratx.com (NMRA) - Consensus Target|SCLX (Scilex) - Consensus Target|Tevogen Bio Holdings Inc. - Fair Value Consensus|Price Target Chart Alpha Cognition Inc|Consensus Target cogrx.com (CGTX)|Analyst Consensus Forecast IKT|SAVA - Average Forecast Price|Analyst Consensus Forecast ASRT (Assertio)|COYA: Broker Consensus Forecast|VistaGen Therapeutics Inc - Analyst Consensus Forecast|Analyst Median Target Ovid Therapeutics Inc. OVID|ABOS: Analyst Consensus Forecast|Consensus Target cervomed.com|ATHE (Alterity Therapeutics Ltd.) - Analyst Consensus Forecast|Analyst Consensus Forecast Clene Nanomedicine|Price Target Chart PepGen Inc. (PEPG)|Price Target Chart JUNS (jupiterneurosciences.com)|Relmada Therapeutics - Consensus Target|Fair Value Consensus ANVS|Grace Tx - Analyst Consensus Forecast|Analyst Median Target Firefly Neuroscience, Inc. AIFF|anewmeds.com (KLTO) - Price Target Chart|Broker Consensus Forecast NRSN|RVPH (Reviva Pharmaceuticals) - Analyst Consensus Forecast|Consensus Target MetaVia, Inc. (MTVA)|Consensus Target NRXS (NeurAxis)|Analyst Median Target heliusmedical.com|Passage Bio - Consensus Target|NEUP - Consensus Target|Minerva Neurosciences - Analyst Consensus Forecast|Average Forecast Price athira.com|Addex Therapeutics Ltd (ADXN) - Price Target Chart|Broker Consensus Forecast ALZN|CYCN (Cyclerion Therapeutics Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Protagenic|Price Target Chart Pasithea Therapeutics (KTTA)|cortigent.com - Broker Consensus Forecast|Analyst Consensus Forecast ATXI (Avenue Therapeutics, Inc.)|Brainstorm Cell Therapeutics Inc. (BCLI) - Average Forecast Price|CARA: Consensus Target|CHRO - Analyst Consensus Forecast|eliemtx.com (ELYM) - Price Target Chart|Intra-Cellular Therapies, Inc. - Fair Value Consensus|Price Target Chart Longboard Pharmaceuticals, Inc.|Average Forecast Price Marinus Pharmaceuticals Inc MRNS|Analyst Consensus Forecast NKGN|Analyst Consensus Forecast NeuroBo Pharma (NRBO)|Price Target Chart Sage Therapeutics, Inc. SAGE|SNPX: Broker Consensus Forecast|Trevena - Analyst Consensus Forecast|Average Forecast Price Vigil Neuroscience|CERE (Cerevel) - Consensus Target
